Skip to content

Evaluation of the efficacy of tumor suppression prescription combined with standard adjuvant therapy after surgery in patients with locally advanced cervical cancer

Evaluation of the efficacy of tumor suppression prescription combined with standard adjuvant therapy after surgery in patients with locally advanced cervical cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001113
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Treatment group:Postoperative standard adjuvant treatment + increase and exemption of tumor suppression prescription granules
Control group:Postoperative standard adjuvant therapy + placebo granules

Sponsors

Obstetrics & Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with a clear pathological diagnosis of cervical cancer, surgical pathological stage IB3, IIA2, IIIC (FIGO stage in 2018), and high-risk factors requiring postoperative complementary treatment. (2) Age 18-70 years old. (3) Normal cardiopulmonary function, liver and kidney function. (4) Subjects who are informed and voluntarily sign the informed consent form. (5) Karnofsky (KPS) score = 70 points.

Exclusion criteria

Exclusion criteria: (1) Severe liver and kidney function impairment. (2) Pregnancy or lactation. (3) Malignant tumors in other parts (= 5 years). (4) Allergy and intolerance to chemotherapy and other drugs. (5) Patients with severe psychological or mental illness. (6) Those who have poor compliance with treatment or follow-up. (7) Karnofsky (KPS) score < 70 points.

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival;

Secondary

MeasureTime frame
Overalsurvival;Quality of Life scale score;The occurrence of adverse reactions in radiotherapy, chemotherapy and immunotherapy;mental state;

Countries

China

Contacts

Public ContactJianghua

Obstetrics & Gynecology Hospital of Fudan University

jianghua@fudan.edu.cn13601978182

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026